MS
Mangala Subhash Wagh
About Mangala Subhash Wagh
Data last updated:
Mangala Subhash Wagh is a Director at Symbiosis Hospital And Research Centre Private Limited (since 2004) and Partner at Srrc Pharmacy Llp (since 2026). The companies operate in Healthcare. The largest current company by reported revenue is Symbiosis Hospital And Research Centre Private Limited at ₹5.80 Cr (FY 2025).
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
| Director | 30 Sep 2004 | 2000 | ₹5.80 Cr (FY 2025) | Active | |
| Partner | 02 Jul 2026 | 2026 | Active |
Board colleagues of Mangala Subhash Wagh
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Mangala Subhash Wagh
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Mangala Subhash Wagh
Mangala Subhash Wagh currently holds 2 directorships: Symbiosis Hospital And Research Centre Private Limited (Director, since 30 Sep 2004, revenue ₹5.80 Cr (FY 2025)); Srrc Pharmacy Llp (Partner, since 02 Jul 2026).
Mangala Subhash Wagh was first appointed on 30 Sep 2004 as Director at Symbiosis Hospital And Research Centre Private Limited. The most recent appointment on record is 02 Jul 2026 at Srrc Pharmacy Llp.
The current boards of Mangala Subhash Wagh's companies include Anuradha Murlidhar Warunjikar (Symbiosis Hospital And Research Centre Private Limited), Mohommedrafique Bagwan Babalal (Symbiosis Hospital And Research Centre Private Limited), Prasad Gajanan Deshmukh (Symbiosis Hospital And Research Centre Private Limited), Ramesh Chimaji Chougule (Symbiosis Hospital And Research Centre Private Limited), Shaila Prashant Kapre (Symbiosis Hospital And Research Centre Private Limited), Shrikant Anant Bokil (Symbiosis Hospital And Research Centre Private Limited), among others.